Compare VF Corp (VFC) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VF Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? VF Corp trades at $14.7 (market cap $5.81B), while Vertex Pharmaceuticals Incorporated trades at $524.87 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 23.1× VF Corp's market cap, and VF Corp pays a 2.44% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VFC | VRTX | |
|---|---|---|
Market Cap | $5.81B | $134.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $21.55 | $529.65 |
52-Week Low | $12.21 | $376.62 |
Enterprise Value | $10.09B | $128.37B |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VFC trades at $14.70, down 1.34% over 24 hours, with a bearish technical signal and neutral oscillators. Recent earnings showed a Q2 2026 miss with a loss of $0.27 per share versus a $0.22 loss expected, though Q4 2025 beat expectations. Revenue declined to $9.50 billion in 2025, with a net loss of $189.72 million, while the company maintains a gross margin of 54.97%. Deleveraging progress continues, but Vans brand performance remains a headwind.
The outlook is mixed; analyst consensus is a 'Hold' with a $17.44 price target, implying potential upside. Risks include persistent Vans weakness, macroeconomic pressures, and competitive dynamics. Positive catalysts include raised fiscal 2027 revenue guidance and margin improvements, but execution on brand turnaround is critical for stock appreciation.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
